Text Size

Study of INS365 Ophthalmic Solution in Subjects With Dry Eye Disease

This study has been completed.
Sponsor:
Information provided by:
Merck
ClinicalTrials.gov Identifier:
NCT00403715
First received: November 22, 2006
Last updated: May 20, 2013
Last verified: May 2013
History of Changes
  Purpose

The purpose of this trial is to compare the effectiveness and safety of INS365 Ophthalmic Solution with Placebo when applied topically in subjects with dry eye disease.


Condition Intervention Phase
Dry Eye Disease
 Drug: diquafosol tetrasodium (INS365) Ophthalmic Solution
 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Multi-Center, Double-Masked, Randomized, Placebo-Controlled, Dose-Ranging Study of Multiple Ocular Instillations of INS365 Ophthalmic Solution vs. Placebo in Subjects With Dry Eye Disease

Resource links provided by NLM:

MedlinePlus related topics: Eye Diseases
U.S. FDA Resources

Further study details as provided by Merck:

Primary Outcome Measures:
  • change in dry eye testing measures and symptoms

Secondary Outcome Measures:
  • change in dry eye testing measures and symptoms

Estimated Enrollment: 500
Study Start Date: February 2001
Primary Completion Date: September 2002 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • best corrected visual acuity in both eyes of at least +0.7
  • six-month documented history of dry eye disease
  • at least mild severity in 2 of the 4 dry eye symptoms
  • unanesthetized Schirmer score of less than or equal to 7mm
  • corneal fluorescein staining of greater than or equal to 4 (out of 15)

Exclusion Criteria:

  • nasally stimulated Schirmer score of less than 3mm in subjects with an initial Schirmer score of 0mm
  • ongoing contact lens wear
  • current topical ophthalmic medication use
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00403715

Sponsors and Collaborators
Merck
Investigators
Study Director: Amy Schaberg, BSN
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00403715     History of Changes
Other Study ID Numbers: 03-104
Study First Received: November 22, 2006
Last Updated: May 20, 2013
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Keratoconjunctivitis Sicca
Dry Eye Syndromes
Eye Diseases
Keratoconjunctivitis
Conjunctivitis
 Conjunctival Diseases
Keratitis
Corneal Diseases
Lacrimal Apparatus Diseases

ClinicalTrials.gov processed this record on June 18, 2013